The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.


Updates from The Motley Fool

Latest updates on Vericel from Fool.com.


Stock Performance

View Interactive VCEL Charts
Sponsored by

Key Data Points

Primary metrics and data points about Vericel.
Current Price: $2.70
Prev Close: $2.75
Open: $2.75
Bid: $2.65
Ask: $2.80
Day's Range: $2.65 - $2.80
52wk Range: $1.96 - $6.69
Volume: 436,332
Avg Vol 433,396
Market Cap: $88M
P/E (ttm): -2.33
EPS (ttm): ($1.18)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Vericel.
CAPS Rating 1 out of 5
 
106 Outperform
28 Underperform
CAPS All Stars
 
9 Outperform
12 Underperform

How do you think Vericel will perform against the market?



You pick for Vericel is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Nick Colangelo, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Vericel.

The regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers